Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6381826 | 0.93 | MAPK1 (0.67) | TSHRMAPK1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL1808476 | 0.93 | TSHR (0.63) | TSHRMAPK1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL310621 | 0.89 | TSHR (0.71) | TSHRMAPK1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL31474384 | 0.89 | TSHR (0.71) | TSHRMAPK1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL14430174 | 0.88 | MAPT (0.68) | TSHRMAPK1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL9544375 | 0.87 | HPGD (0.63) | TSHRMAPK1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL19422126 | 0.87 | MAPT (0.66) | TSHRMAPK1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL2149738 | 0.87 | MAPT (0.66) | TSHRMAPK1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL5216700 | 0.86 | MGLL (0.62) | TSHRMAPTSMN1; SMN2CYP1A2CYP3A4 | |
| Veratric Acid Methyl Ester SCHEMBL29573244 | 0.86 | MAPT (0.86) | TSHRMAPTSMN1; SMN2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117550979-B | Vanillic acid derivative and preparation method and application thereof | 广西师范大学 | 2025-03-11 | — | — | CN | disclosed |
| CN-117550979-A | Vanillic acid derivative and preparation method and application thereof | 广西师范大学 | 2024-02-13 | — | — | CN | disclosed |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2018-03-08 | — | — | US | disclosed |
| EP-2268623-B9 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2017-10-19 | — | — | US | disclosed |
| US-9730937-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| EP-3147281-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2016-07-14 | — | — | US | disclosed |
| US-6384080-B1 | TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| WO-2001068186-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
| US-6288082-B1 | COMPOUNDS SUCH AS 6,7-DIETHOXY-4-(INDAN-5-YLAMINO) -QUINOLINE-3-CARBONITRILE USED AS ANTINEOPLASTIC AGENTS AND IN THE TREATMENT OF POLYCYCSTIC KIDNEY DISEASE | AMERICAN CYANAMID COMPANY | 2001-09-11 | — | — | US | disclosed |
| EP-1117659-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | disclosed |
| EP-1080069-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-07 | — | — | EP | disclosed |
| WO-2000018761-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
| EP-0973746-A1 | SUBSTITUTED 3-CYANO QUINOLINES | American Cyanamid Company (US) | 2000-01-26 | — | — | EP | disclosed |
| US-6002008-A | Substituted 3-cyano quinolines | AMERICAN CYANAMID COMPANY | 1999-12-14 | — | — | US | disclosed |
| WO-1999054284-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
| WO-1998043960-A1 | SUBSTITUTED 3-CYANO QUINOLINES | AMERICAN CYANAMID COMPANY (US) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | BRAF, RAF1, ARAF | TSHR 1876/4885MAPK1 66/4885MAPT 3020/4885 |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | TSHR 1876/4885MAPK1 66/4885MAPT 3020/4885 |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | TSHR 1876/4885MAPK1 66/4885MAPT 3020/4885 |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | TSHR 4469/4885MAPK1 4304/4885MAPT 4665/4885 |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | TSHR 3778/4885MAPK1 3272/4885MAPT 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.